REDEFINE-3

Sponsor: NOVONORDISK

The REDEFINE-3 study evaluates CagriSema’s effects on cardiovascular events in individuals with obesity and cardiovascular disease. Participants receive either CagriSema or a placebo through weekly injections for about three years. The study aims to understand CagriSema’s safety and effectiveness in treating obesity-related cardiovascular conditions, such as heart attacks and strokes. Women must not be pregnant, breastfeeding, or planning pregnancy during the study. CagriSema combines cagrilintide and semaglutide, medications that aid in weight loss. The study contributes to understanding obesity, related diseases, and how CagriSema functions.
The REDEFINE-3 study incorporates a placebo control group alongside the group receiving CagriSema. The placebo is a dummy medicine that does not have any active ingredients or effects on the body. Participants are assigned to either the CagriSema group or the placebo group by chance, ensuring an unbiased comparison between the two treatments. This design helps researchers assess the specific effects of CagriSema by comparing it to a control group that does not receive the active medication.

Studyteam:
Subinvastigator: Dr. Kim Ricken-Pierens